Past, Present, and Future of Anticancer Nanomedicine
Kyungeun Kim,1 Dongwoo Khang1– 4 1College of Medicine, Gachon University, Incheon 21999, South Korea; 2Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, South Korea; 3Gachon Advanced Institute for Health Science & Technology (GAIHST), Gachon University, In...
Guardado en:
Autores principales: | Kim K, Khang D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf0b07af70bb412cb46dd2db9f52e6e5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
por: Jiang Y, et al.
Publicado: (2020) -
Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
por: Florian Janisch, et al.
Publicado: (2021) -
Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy
por: Yu-Ling Yang, et al.
Publicado: (2021) -
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021) -
Current Potential Therapeutic Approaches against SARS-CoV-2: A Review
por: Dharmendra Kumar Yadav, et al.
Publicado: (2021)